Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyvalent human immunoglobulin is a purified form of human immunoglobulin G and other proteins derived from pooled human plasma from thousands of donors. It contains primarily IgG (with four subclasses: IgG1, IgG2, IgG3, and IgG4) and works through multiple mechanisms including Fc-dependent and F(ab')2-dependent actions. It interacts with cytokines, complement, Fc receptors, and several cell surface immunocompetent molecules, impacting different effector cells of the immune system and regulating a wide range of genes. IVIG is used for replacement therapy in immunodeficiency disorders and as an immunomodulator in various autoimmune and inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyvalent human immunoglobulin.